At the time of writing, Day One Biopharmaceuticals Inc [DAWN] stock is trading at $14.26, down -3.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DAWN shares have gain 4.62% over the last week, with a monthly amount glided 4.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on August 01, 2024, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $24 from $11. Previously, Needham reaffirmed its Buy rating on April 24, 2024, and elevated its price target to $33. On April 25, 2023, downgrade downgraded it’s rating to Underperform and revised its price target to $9 on the stock. CapitalOne started tracking the stock assigning a Overweight rating and suggested a price target of $40 on February 08, 2023. Oppenheimer initiated its recommendation with a Perform. H.C. Wainwright started tracking with a Buy rating for this stock on December 15, 2022, and assigned it a price target of $35. In a note dated December 14, 2022, Needham initiated an Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Day One Biopharmaceuticals Inc fluctuated between $9.67 and $18.07. Currently, Wall Street analysts expect the stock to reach $38.8 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $14.26 at the most recent close of the market. An investor can expect a potential return of 172.09% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -33.42%, Pretax Profit Margin comes in at -18.96%, and Net Profit Margin reading is -19.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.23 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.80 points at the first support level, and at 13.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.80, and for the 2nd resistance point, it is at 15.35.
Ratios To Look Out For
It is important to note that Day One Biopharmaceuticals Inc [NASDAQ:DAWN] has a current ratio of 4.09. As well, the Quick Ratio is 4.09, while the Cash Ratio is 2.56. Considering the valuation of this stock, the price to sales ratio is 152.80, the price to book ratio is 4.08.
Transactions by insiders
Recent insider trading involved Blackman Samuel C., HEAD OF R&D, that happened on Sep 10 ’24 when 30000.0 shares were sold. GENERAL COUNSEL, Dubow Adam completed a deal on Aug 16 ’24 to sell 3202.0 shares. Meanwhile, COO, CFO AND SECRETARY York Charles N II sold 2633.0 shares on Aug 16 ’24.
